Esperion (ESPR) has released an update to notify the public and investors about an entry into a material definitive agreement.
Esperion Therapeutics, Inc. has entered into an Underwriting Agreement with Jefferies LLC for a public offering of 56,700,000 shares of common stock at $1.50 per share, with an option for underwriters to purchase an additional 8,505,000 shares. Upon the full exercise of the option, the company anticipates proceeds of approximately $90.8 million, net of underwriting discounts and expenses, with the offering’s closure expected on January 23, 2024. The offering is based on a registration statement previously filed and declared effective, and includes customary legal terms, representations, warranties, and indemnification obligations.
For further insights into ESPR stock, check out TipRanks’ Stock Analysis page.
